Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Treasury Shares (2016 - 2025)

Integra Lifesciences Holdings' Treasury Shares history spans 17 years, with the latest figure at $689.2 million for Q4 2025.

  • For Q4 2025, Treasury Shares changed 0.32% year-over-year to $689.2 million; the TTM value through Dec 2025 reached $689.2 million, changed 0.32%, while the annual FY2025 figure was $689.2 million, 0.32% changed from the prior year.
  • Treasury Shares for Q3 2025 was $14.4 million at Integra Lifesciences Holdings, roughly flat from $14.4 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $14.4 million in Q4 2024 and bottomed at $446000.0 in Q3 2024.
  • The 5-year median for Treasury Shares is $6.8 million (2022), against an average of $8.8 million.
  • The largest annual shift saw Treasury Shares fell 0.33% in 2021 before it skyrocketed 78.39% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $234.4 million in 2021, then soared by 54.77% to $362.9 million in 2022, then soared by 78.39% to $647.3 million in 2023, then increased by 6.81% to $691.4 million in 2024, then fell by 0.32% to $689.2 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Treasury Shares are $689.2 million (Q4 2025), $690.0 million (Q3 2025), and $690.0 million (Q2 2025).